Asia-Pacific
Mathew Lucas has joined Pearce IP after spending more than 25 years at IPH-owned firm Davies Collison Cave
Duarte Lima, MD of Spruson & Ferguson’s Asia practice, says practitioners must adapt to process changes within IP systems, as well as be mindful of the implications of tech on their practices
Jennifer Che explains how taking on the managing director role at her firm has offered a new perspective, and why Hong Kong is seeing a life sciences boom
Counsel for SEP owners and implementers are keeping an eye on the case, which could help shape patent enforcement strategy for years to come
Sponsored
Sponsored
-
Sponsored by Saint Island International Patent & Law OfficesMing-Yeh Lin of Saint Island International Patent & Law Offices reports on a Taiwanese Intellectual Property and Commercial Court ruling that has ramifications for whether certain private documents can serve as prior art references -
Sponsored by Bird & BirdMeyke Rietveld and Clemens Molle of Bird & Bird, along with Emma Ren from the association team at Beijing Lawjay Partners, discuss the first copyright cases in China and the EU dealing with training AI models, and newly enacted legislation in this field
-
Sponsored by Tilleke & GibbinsLoc Xuan Le, Duc Anh Tran, and Linh Duy Mai of T&G Law Firm LLC, the local associate firm of Tilleke & Gibbins in Vietnam, report on the country’s first criminal trial involving copyright and related rights infringement
-
Sponsored by Tilleke & GibbinsLinh Thi Mai Nguyen and Chi Lan Dang of Tilleke & Gibbins say regulations concerning the new Inspection and Appeal Department and a 2023 circular are steps towards improved handling of intellectual property appeals
-
Sponsored by Remfry & SagarAarti Aggarwal of Remfry & Sagar reports that a decision concerning a company licensed to use the Nokia brand name has confirmed that generic concepts or ideas cannot be protected through copyright
-
Sponsored by RNA, Technology and IP AttorneysRanjan Narula and Suvarna Pandey of RNA, Technology and IP Attorneys consider the implications of a High Court of Delhi ruling concerning a patented compound used to treat non-small cell lung cancer
